IFRX News and Press, InflaRx N.V.

JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...

Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...

JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...

2024-05-08 11:57:53 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips InflaRx (NASDAQ: IFRX ) just reported results for the first quarter of 2024. InflaRx reported earnings per share of -18 cents. This was above the analyst estimate for EPS ...

2024-05-08 07:36:06 ET More on InflaRx Seeking Alpha’s Quant Rating on InflaRx Historical earnings data for InflaRx Financial information for InflaRx Read the full article on Seeking Alpha For further details see: InflaRx GAAP EPS of - ...

Virtual R&D event to be held on June 5, 2024 from 12:00 to 2:00 PM EDT – highlighting company plans for INF904 and the opportunity, the role of C5aR in ch ronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) and C5a/C5aR signaling in human inflammatory diseases ...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

2024-05-07 13:21:34 ET More on InflaRx Seeking Alpha’s Quant Rating on InflaRx Historical earnings data for InflaRx Financial information for InflaRx Read the full article on Seeking Alpha For further details see: InflaRx Q1 2024 Earnings P...

2024-05-07 11:00:00 ET Major earnings expected before the bell on Wednesday include: Brookfield Asset Management ( BAM ) Emerson Electric ( EMR ) Shopify ( SHOP ) Teva Pharmaceutical Industries ( TEVA ) Uber Technologies ( UBER ) Read the fu...

JENA, Germany, April 30, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will report its first quarter 2024 financial and operating results on May 8, 2024, befor...